ImmunityBio Profit Margin

ImmunityBio (IBRX) currently reports a profit margin of -598.56% as of June 2026. That compares with -650.32% in the prior-year period — up 8.0% year over year. That is below the Healthcare sector average of 21.34%. Use the charts on this page to explore ImmunityBio's profit margin history and peer comparisons.

ImmunityBio's profit margin increased from -650.32% to -598.56% — a 8.0% year-over-year increase (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

ImmunityBio's profit margin of -598.56% is lower than the Healthcare sector average of 21.34%. That is roughly 2905.5% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but ImmunityBio's current -598.56% should be judged against Healthcare norms (sector average: 21.34%) and against IBRX's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -598.56%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 21.34%. From there, open related valuation or income-statement pages for ImmunityBio, and consider following IBRX for alerts when major investors trade the stock.